ERBB2 and breast carcinoma: While these capture the majority of somatic alterations in breast cancer, we did not assess gene amplifications or fusions which are potential genomic driver or tumor suppressor alterations that are relevant for genotype-matched treatment selection, such FGFR1 amplification or fusions, BRCA1/2 mutations, NTRK fusions, PIK3CA fusions and ERBB2 fusions [36].